Takeda Pharmaceutical Co Ltd (SSE:4502)
円 4300 0 (0%) Market Cap: 6.48 Til Enterprise Value: 10.85 Til PE Ratio: 45.22 PB Ratio: 0.89 GF Score: 76/100

Novartis AG to Discuss Acquisition of Xiidra® from Takeda Pharmaceutical Co Ltd Call Transcript

May 09, 2019 / 12:00PM GMT
Release Date Price: 円4050
Operator

Good morning and good afternoon and welcome to Novartis investor call and webcast on the proposed Xiidra acquisition. (Operator Instructions) And the conference is being recorded. (Operator Instructions) A recording of the conference call including the Q&A session will be available on our website shortly after the call ends. (Operator Instructions) And with that, I would now like to hand over the conference to Mr. Samir Shah, Global Head of Investor Relations. Please go ahead, sir.

Samir Shah
Novartis AG - Global Head of IR

Thank you very much, and good morning and good afternoon, everybody. And thanks for your time yet again to join us on our investor call today. So with us, we have Paul Hudson, CEO of Novartis Pharmaceuticals; Dirk Sauer, who's head of the global franchise from a development perspective for ophthalmology; and Patrick Mooney, who's the U.S. franchise head for ophthalmology from a commercial perspective.

Before I hand across to Paul, I'd just like to read you the safe harbor statement. The information presented today contains

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot